Corbus Pharmaceuticals Holdings (CRBP) Total Non-Current Liabilities (2016 - 2024)

Corbus Pharmaceuticals Holdings' Total Non-Current Liabilities history runs 7 years deep, the most recent figure standing at $13.5 million for Q4 2024.

• On a quarterly basis, Total Non-Current Liabilities fell 61.71% year-over-year to $13.5 million in Q4 2024; TTM through Dec 2024 was $13.5 million, a 61.71% decrease from a year earlier, with the FY2024 full-year figure at $13.5 million, down 61.71% from the prior year.
• Total Non-Current Liabilities slipped to $13.5 million in Q4 2024 per CRBP's latest filing, from $13.7 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $57.0 million in Q4 2020 and bottomed at $13.5 million in Q4 2024.
• The 5-year median for Total Non-Current Liabilities is $34.2 million (2023), against an average of $34.2 million.
• Across the five-year window, Total Non-Current Liabilities increased 12.76% in 2023 and sank 61.94% in 2024, its largest moves.
• Year by year, Total Non-Current Liabilities stood at $57.0 million in 2020, then sank by 32.3% to $38.6 million in 2021, then dropped by 13.73% to $33.3 million in 2022, then rose by 5.51% to $35.1 million in 2023, then slumped by 61.71% to $13.5 million in 2024.
• Per Business Quant, the three latest CRBP Total Non-Current Liabilities figures stand at $13.5 million (Q4 2024), $13.7 million (Q3 2024), and $26.4 million (Q2 2024).